TNC Antikörper

Produktnummer ABIN1109217

Produktdetails anti-TNC Antikörper

Target: TNC (Tenascin C (TNC))

Reaktivität: Human, Meerschweinchen, Kaninchen

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser TNC Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (Frozen Sections) (IHC (fro)), Enzyme Immunoassay (EIA)

Spezifität: The antibody clone EB2 reacts with the 4th and 5th fibronectin-like repeats of Human Tenascin-C polypeptides of Mr 250000 and 180000.

Kreuzreaktivität (Details): Species reactivity (tested):Human, Guinea Pig and Rabbit.

Aufreinigung: Ig Fraction

Immunogen: Purified Tenascin-C from human fetal fibroblasts. Hybridoma produced by fusion between myeloma cells and Balb/c spleen cells.

Klon: EB2

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 0.1 mg/mL

Buffer: PBS, 0.09 % Sodium Azide, 1.0 % BSA

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Informationen zur Lagerung: Store the antibody undiluted at 2-8 °C.

Details zu TNC

Target: TNC (Tenascin C (TNC))

Andere Bezeichnung: Tenascin / TNC / HXB (TNC Produkte)

Synonyme: tn antikoerper, 150-225 antikoerper, GMEM antikoerper, GP antikoerper, HXB antikoerper, JI antikoerper, TN antikoerper, TN-C antikoerper, AI528729 antikoerper, C130033P17Rik antikoerper, Hxb antikoerper, Ten antikoerper, cytotactin antikoerper, tenascin-C antikoerper, P230 antikoerper, tenc antikoerper, wu:fk04d02 antikoerper, tenascin C L homeolog antikoerper, tenascin C antikoerper, tnc.L antikoerper, TNC antikoerper, MCYG_00667 antikoerper, tnc antikoerper, Tnc antikoerper

Hintergrund: Tenascins were first characterized in the early 1980's. Since then hundreds of publications on tenascin in normal tissues, pathologically reactive tissues and carcinomas have been published. However, only recently more elective studies have been done. In these studies retrospective material from pathology files has been studied as well as larger fresh material collected during several years from patients. These studies have now attempted to reveal more specific points in carcinogenesis and pathological tissue reactions. It has been demonstrated that tenascin immunoreactivity in breast carcinoma cells could be indicative of metastasis and survival. Recent studies using retrospective material showed that the expression of tenascin in invasion border of early breast cancer significantly correlates with higher risk of distant metastasis. These studies have been continued now and the preliminary results clearly suggest that expression of tenascin in invasion border of early breast cancer is significantly associated with proliferative activity and higher risk of local recurrence. This result implicates a wide application for tenascin antibodies in the breast pathology. The point is that tenascin expression may suggest situations in which even small breast carcinomas may need more intensive complementary therapy (chemotherapy etc.). Recent studies have also shown that tenascin is significantly increased in airway basement membrane of asthmatics and rapidly decreases by inhaled steroid. This result suggests that tenascin expression may be used to monitor the disease status and outcome of treatment in different types of asthma.Synonyms: Cytotactin, GMEM, GP 150-225, Glioma-associated-extracellular matrix antigen, Hexabrachion, Myotendinous antigen, Neuronectin, TN-C, Tenascin-C

Gen-ID: 3371

NCBI Accession: NP_002151

UniProt: P24821

Pathways: Regulation of Muscle Cell Differentiation, Regulation of Cell Size, Skeletal Muscle Fiber Development